Program
cemiplimab
Also written as “Cemiplimab”, “REGN2810” and “REGN2810/chemo/ipi”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Basal Cell · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 3516 open or running | phase 3since Mar 3, 2017 | Feb 2, 2015 | Mar 22, 2027phase 3 · NCT06246916 |
| BioNTech | 20 open or running | phase 2since Apr 21, 2020 | Apr 21, 2020 | none ahead |
| Maia Biotechnology | 11 open or running | phase 3since Mar 20, 2025 | Mar 20, 2025 | Jul 31, 2027phase 3 · NCT06908304 |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 2since May 22, 2023 | May 22, 2023 | none ahead |
| Sanofi | 10 open or running | phase 2since Jun 19, 2017 | Jun 19, 2017 | none ahead |
| SillaJen | 10 open or running | phase 2since Sep 19, 2017 | Sep 19, 2017 | none ahead |
| Vyriad | 11 open or running | phase 2since Feb 25, 2020 | Feb 25, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Feb 2, 2015.
- Sep 23, 2022Phase 2 study in Advanced Non-Small Cell Lung CancerRegeneron Pharmaceuticals · NCT05557591 · 51 enrolled · United States, Georgia, Germany and more
- May 22, 2023Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05882734 · 61 enrolled · United States, Belgium, France and more
- Nov 9, 2023Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06190951 · 151 enrolled · United States, Australia, Austria and more
- Jan 30, 2024Phase 3 study in MelanomaRegeneron Pharmaceuticals · NCT06246916 · 560 planned · United States, Canada
- Apr 22, 2024Phase 2 study in Cutaneous Squamous Cell CarcinomaRegeneron Pharmaceuticals · NCT06384820
- May 9, 2024Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06413680 · 240 planned · United States
- Jun 6, 2024Phase 1 study in Carcinoma, Ovarian EpithelialRegeneron Pharmaceuticals · NCT06469281 · 90 planned · United States
- Sep 3, 2024Phase 3 study in Skin NeoplasmsRegeneron Pharmaceuticals · NCT06585410 · 369 planned · United States, Australia
- Jan 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckRegeneron Pharmaceuticals · NCT06769698 · 120 planned · United States, Australia, France and more
- Feb 24, 2025Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06848088 · 28 enrolled · United States, Ireland
- Mar 20, 2025Maia Biotechnology's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Maia BiotechnologyMaia Biotechnology · NCT06908304 · 300 planned · Poland, Romania, Taiwan and more
- Apr 28, 2026Phase 2 study in GliomaRegeneron Pharmaceuticals · NCT07567469 · 120 planned
- Sep 1, 2026Phase 2 study in Skin NeoplasmsRegeneron Pharmaceuticals · NCT07808515 · 135 planned
- Nov 10, 2026Primary completion moved from 2029-10-10 to 2030-10-09Date moved laterphase 2 · +12 months · NCT06848088
Ahead
- Nov 2, 2026Primary completion: phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06190951
- Nov 13, 2026Primary completion: phase 2 study in Advanced Solid TumorsRegeneron Pharmaceuticals · NCT04626635
- Mar 22, 2027Primary completion: phase 3 study in MelanomaRegeneron Pharmaceuticals · NCT06246916
- Apr 29, 2027Primary completion: phase 1 study in Neoplasm MetastasisRegeneron Pharmaceuticals · NCT05259709
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07808515Skin Neoplasms | 2 | Not yet recruiting | Regeneron Pharmaceuticals | Nov 13, 2030 | 135 |
| NCT07567469Glioma | 2 | Not yet recruiting | Regeneron Pharmaceuticals | Aug 27, 2032 | 120 |
| NCT06908304Carcinoma, Non-Small-Cell Lung · Poland, Romania, Taiwan and more | 3 | Recruiting | Maia Biotechnology | Jul 31, 2027 | 300 |
| NCT06848088Melanoma · United States, Ireland | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Oct 9, 2030 | 28 |
| NCT06769698Squamous Cell Carcinoma of Head and Neck · United States, Australia, France and more | 2 | Recruiting | Regeneron Pharmaceuticals | Jun 4, 2028 | 120 |
| NCT06585410Skin Neoplasms · United States, Australia | 3 | Recruiting | Regeneron Pharmaceuticals | May 3, 2030 | 369 |
| NCT06469281Carcinoma, Ovarian Epithelial · United States | 1 | Recruiting | Regeneron Pharmaceuticals | May 27, 2030 | 90 |
| NCT06413680Melanoma · United States | 2 | Recruiting | Regeneron Pharmaceuticals | Feb 3, 2030 | 240 |
| NCT06384820Cutaneous Squamous Cell Carcinoma | 2 | Withdrawn | Regeneron Pharmaceuticals | Jun 8, 2026 | 0 |
| NCT06246916Melanoma · United States, Canada | 3 | Recruiting | Regeneron Pharmaceuticals | Mar 22, 2027 | 560 |
| NCT06190951Melanoma · United States, Australia, Austria and more | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Nov 2, 2026 | 151 |
| NCT05882734Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jul 15, 2026 | 61 |
| NCT05557591Advanced Non-Small Cell Lung Cancer · United States, Georgia, Germany and more | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Jan 26, 2028 | 51 |
| NCT05259709Neoplasm Metastasis · Netherlands | 1 | Active, not recruiting | Regeneron Pharmaceuticals | Apr 29, 2027 | 22 |
| NCT04626635Advanced Solid Tumors · United States, France, Israel and more | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Nov 13, 2026 | 548 |
| NCT04526899Melanoma · United States, Australia, Germany and more | 2 | Completed | BioNTech | Jan 25, 2024 | 184 |
| NCT04382898Prostatic Neoplasms · United States, Germany, Hungary and more | 2 | Terminated | BioNTech | Jan 23, 2024 | 75 |
| NCT04373083Hodgkin Disease | 2 | Withdrawn | Regeneron Pharmaceuticals | Dec 20, 2022 | 0 |
| NCT04291105Melanoma · United States, Brazil | 2 | Active, not recruiting | Vyriad | Oct 2026 | 87 |
| NCT04154943Cutaneous Squamous Cell Carcinoma · United States, Australia, Germany | 2 | Completed | Regeneron Pharmaceuticals | Dec 1, 2021 | 79 |
| NCT03969004Cutaneous Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Regeneron Pharmaceuticals | Jan 7, 2028 | 415 |
| NCT03916627Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Mar 31, 2025 | 65 |
| NCT03889912Carcinoma, Basal Cell · United States, Australia, Netherlands | 1 | Completed | Regeneron Pharmaceuticals | Nov 13, 2025 | 97 |
| NCT03690869Central Nervous System Neoplasms · United States | 2 | Terminated | Regeneron Pharmaceuticals | May 10, 2023 | 57 |
| NCT03580694Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | Regeneron Pharmaceuticals | Dec 4, 2019 | 17 |
| NCT03564340Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Regeneron Pharmaceuticals | May 10, 2027 | 890 |
| NCT03515629Carcinoma, Non-Small-Cell Lung · United States, Italy, Lithuania | 3 | Terminated | Regeneron Pharmaceuticals | Jul 29, 2021 | 5 |
| NCT03430063Advanced Non-Small Cell Lung Carcinoma · United States, Belgium, France and more | 2 | Terminated | Regeneron Pharmaceuticals | Oct 27, 2021 | 28 |
| NCT03409614Carcinoma, Non-Small-Cell Lung · United States, Austria, China and more | 3 | Completed | Regeneron Pharmaceuticals | Feb 27, 2025 | 789 |
| NCT03294083Carcinoma, Renal Cell · United States, Australia, South Korea | 2 | Completed | SillaJen | Feb 16, 2023 | 95 |
| NCT03257267Carcinoma, Squamous Cell · United States, Australia, Belgium and more | 3 | Completed | Regeneron Pharmaceuticals | Mar 15, 2021 | 608 |
| NCT03233139Advanced Malignancies · Japan | 1 | Active, not recruiting | Regeneron Pharmaceuticals | Sep 30, 2027 | 146 |
| NCT03198130Recurrent Squamous Cell Carcinoma of Head · Korea, Republic of, United Kingdom | 1 | Completed | Regeneron Pharmaceuticals | Jun 27, 2019 | 33 |
| NCT03194867Multiple Myeloma · United States, Australia, Brazil and more | 2 | Completed | Sanofi | Apr 5, 2023 | 109 |
| NCT03132636Carcinoma, Basal Cell · United States, Austria, Belgium and more | 2 | Completed | Regeneron Pharmaceuticals | May 20, 2021 | 138 |
| NCT03088540Carcinoma, Non-Small-Cell Lung · Australia, Belarus, Brazil and more | 3 | Completed | Regeneron Pharmaceuticals | Apr 18, 2025 | 712 |
| NCT03002376Melanoma · Korea, Republic of, Netherlands, Serbia and more | 1 | Completed | Regeneron Pharmaceuticals | Mar 5, 2019 | 47 |
| NCT03005782Neoplasms · United States, Australia, Ireland and more | 1 | Completed | Regeneron Pharmaceuticals | Apr 2, 2024 | 333 |
| NCT02760498Advanced Cutaneous Squamous Cell Carcinoma · United States, Australia, Brazil and more | 2 | Completed | Regeneron Pharmaceuticals | Oct 18, 2023 | 432 |
| NCT02651662Recurrence · United States, Austria, Germany and more | 1 | Completed | Regeneron Pharmaceuticals | Apr 29, 2026 | 105 |
| NCT02520245Advanced Malignancies · United States | 1 | Withdrawn | Regeneron Pharmaceuticals | Nov 2023 | 0 |
| NCT02383212Advanced Cancer · United States, Australia, Spain | 1 | Completed | Regeneron Pharmaceuticals | Nov 18, 2019 | 398 |
How it is read
Names in the registry
- “Cemiplimab”, 23 entries
- “cemiplimab”, 9 entries
- “REGN2810”, 4 entries
- “REGN2810/chemo/ipi”, 2 entries
- “Fianlimab+cemiplimab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Melanoma, 7 studies
- Carcinoma, Basal Cell, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.